The role of massive demographic databases in intractable illnesses: Denomics for dementia

Mark M. Stecker; Morgan R. Peltier; Allison B. Reiss; Mark M. Stecker; Morgan R. Peltier; Allison B. Reiss

doi:10.3934/publichealth.2022043

AIMS Public Health

2022, Volume 9, Issue 3: 618-629. doi: 10.3934/publichealth.2022043

Previous Article Next Article

Perspective Topical Sections

The role of massive demographic databases in intractable illnesses: Denomics for dementia

1.
Fresno Institute for Neuroscience, Fresno, CA 93730, USA
2.
Department of Psychiatry, Hackensack Meridian Health, Neptune City, NJ 07753, USA
3.
NYU Long Island School of Medicine, Mineola, NY, 11501, USA

Received: 13 June 2022 Revised: 10 August 2022 Accepted: 14 August 2022 Published: 23 August 2022

Despite intensive research, effective treatments for many common and devastating diseases are lacking. For example, huge efforts and billions of dollars have been invested in Alzheimer's disease (AD), which affects over 50 million people worldwide. However, there is still no effective drug that can slow or cure AD. This relates, in part, to the absence of an animal model or cellular system that incorporates all the relevant features of the disease. Therefore, large scale studies on human populations and tissues will be key to better understanding dementia and developing methods to prevent or treat it. This is especially difficult because the dementia phenotype can result from many different processes and is likely to be affected by multiple personal and environmental variables. We hypothesize that analyzing massive volumes of demographic data that are currently available and combining this with genomic, proteomic, and metabolomic profiles of AD patients and their families, new insights into pathophysiology and treatment of AD may arise. While this requires much coordination and cooperation among large institutions, the potential for advancement would be life-changing for millions of people. In many ways this represents the next step in the information revolution started by the Human Genome Project.
- dementia,
- therapy,
- dataset,
- medical record,
- privacy,
- environment,
- exposome
Citation: Mark M. Stecker, Morgan R. Peltier, Allison B. Reiss. The role of massive demographic databases in intractable illnesses: Denomics for dementia[J]. AIMS Public Health, 2022, 9(3): 618-629. doi: 10.3934/publichealth.2022043

Related Papers:

Abstract

Despite intensive research, effective treatments for many common and devastating diseases are lacking. For example, huge efforts and billions of dollars have been invested in Alzheimer's disease (AD), which affects over 50 million people worldwide. However, there is still no effective drug that can slow or cure AD. This relates, in part, to the absence of an animal model or cellular system that incorporates all the relevant features of the disease. Therefore, large scale studies on human populations and tissues will be key to better understanding dementia and developing methods to prevent or treat it. This is especially difficult because the dementia phenotype can result from many different processes and is likely to be affected by multiple personal and environmental variables. We hypothesize that analyzing massive volumes of demographic data that are currently available and combining this with genomic, proteomic, and metabolomic profiles of AD patients and their families, new insights into pathophysiology and treatment of AD may arise. While this requires much coordination and cooperation among large institutions, the potential for advancement would be life-changing for millions of people. In many ways this represents the next step in the information revolution started by the Human Genome Project.

Acknowledgments

This work was supported by The Alzheimer's Foundation of America Award [grant number AWD00004772]. The authors would like to acknowledge Mr. Robert Buescher, Mr. Edmonds Bafford and Ms. Deborah Zimmer.

Conflict of interest

All authors declare no conflicts of interest in this paper.

References

[1]	World Health OrganizationWHO fact sheet on dementia (2020). Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
[2]	Hebert LE, Weuve J, Scherr PA, et al. (2013) Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 80: 1778-1783. https://doi.org/10.1212/WNL.0b013e31828726f5
[3]	Livingston G, Huntley J, Sommerlad A, et al. (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396: 413-446. https://doi.org/10.1016/S0140-6736(20)30367-6
[4]	Reiss AB, Montufar N, DeLeon J, et al. (2021) Alzheimer disease clinical trials targeting amyloid: Lessons learned from success in mice and failure in humans. Neurologist 26: 52-61. https://doi.org/10.1097/NRL.0000000000000320
[5]	Reiss AB, Glass AD, Wisniewski T, et al. (2020) Alzheimer's disease: many failed trials, so where do we go from here?. J Investig Med 68: 1135-1140. https://doi.org/10.1136/jim-2020-001297
[6]	McDade E, Llibre-Guerra JJ, Holtzman DM, et al. (2021) The informed road map to prevention of Alzheimer Disease: A call to arms. Mol Neurodegener 16: 49. https://doi.org/10.1186/s13024-021-00467-y
[7]	Vaz M, Silva V, Monteiro C, et al. (2022) Role of aducanumab in the treatment of Alzheimer's disease: Challenges and opportunities. Clinical Interv Aging 17: 797-810. https://doi.org/10.2147/CIA.S325026
[8]	Clement C, Selman LE, Kehoe PG, et al. (2019) Challenges to and facilitators of recruitment to an Alzheimer's disease clinical trial: A qualitative interview study. J Alzheimers Dis 69: 1067-1075. https://doi.org/10.3233/JAD-190146
[9]	Farrelly C (2021) Responsible biology, aging populations and the 50th anniversary of the “War on Cancer”. Biogerontology 22: 429-440. https://doi.org/10.1007/s10522-021-09925-y
[10]	Birney E (2021) The international human genome project. Hum Mol Genet 30: R161-R163. https://doi.org/10.1093/hmg/ddab198
[11]	Khan U, Mehta R, Arif MA, et al. (2020) Pandemics of the past: A narrative review. J Pak Med Assoc 70: S34-S37. https://doi.org/10.5455/JPMA.11
[12]	Van Boeckel TP, Gandra S, Ashok A, et al. (2014) Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 14: 742-750. https://doi.org/10.1016/S1473-3099(14)70780-7
[13]	Evans RS (2016) Electronic health records: Then, now, and in the future. Yearb Med Inform Suppl 1: S48-61. https://doi.org/10.15265/IYS-2016-s006
[14]	Ghayvat H, Pandya S, Bhattacharya P, et al. (2022) CP-BDHCA: Blockchain-Based Confidentiality-Privacy Preserving Big Data Scheme for Healthcare Clouds and Applications. IEEE J Biomed Health Inform 26: 1937-1948. https://doi.org/10.1109/JBHI.2021.3097237
[15]	Hanson CL, Crandall A, Barnes MD, et al. (2021) Protection motivation during COVID-19: A cross-sectional study of family health, media, and economic influences. Health Educ Behav 48: 434-445. https://doi.org/10.1177/10901981211000318
[16]	Vizireanu M, Hruschka D (2018) Lay perceptions of healthy eating styles and their health impacts. J Nutr Educ Behav 50: 365-371. https://doi.org/10.1016/j.jneb.2017.12.012
[17]	Castelvecchi D (2018) Google unveils search engine for open data. Nature 561: 161-162. https://doi.org/10.1038/d41586-018-06201-x
[18]	Graham M (2021) Data for sale: trust, confidence and sharing health data with commercial companies. J Med Ethics . https://doi.org/10.1136/medethics-2021-107464
[19]	Bryant A, Lawrie TA, Dowswell T, et al. (2021) Ivermectin for prevention and treatment of COVID-19 infection: A systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther 28: e434-e460. https://doi.org/10.1097/MJT.0000000000001442
[20]	López-Medina E, López P, Hurtado IC, et al. (2021) Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial. JAMA 325: 1426-1435. https://doi.org/10.1001/jama.2021.3071
[21]	Noel-Storr A (2019) Working with a new kind of team: harnessing the wisdom of the crowd in trial identification. EFSA J 17: e170715. https://doi.org/10.2903/j.efsa.2019.e170715
[22]	Marinescu RV, Oxtoby NP, Young AL, et al. (2019) TADPOLE Challenge: Accurate Alzheimer's disease prediction through crowdsourced forecasting of future data. Predict Intell Med 11843: 1-10. https://doi.org/10.1007/978-3-030-32281-6_1
[23]	Sprange K, Beresford-Dent J, Mountain G, et al. (2021) Journeying through dementia randomised controlled trial of a psychosocial intervention for people living with early dementia: Embedded qualitative study with participants, Carers and interventionists. Clin Interv Aging 16: 231-244. https://doi.org/10.2147/CIA.S293921
[24]	Renoult L, Armson MJ, Diamond NB, et al. (2020) Classification of general and personal semantic details in the Autobiographical Interview. Neuropsychologia 144: 107501. https://doi.org/10.1016/j.neuropsychologia.2020.107501
[25]	Erickson TB, Endo N, Duvallet C, et al. (2021) “Waste not, want not”—leveraging sewer systems and wastewater-based epidemiology for drug use trends and pharmaceutical monitoring. J Med Toxicol 17: 397-410. https://doi.org/10.1007/s13181-021-00853-4
[26]	Yassine HN, Finch CE (2020) APOE alleles and diet in brain aging and Alzheimer's disease. Front Aging Neurosci 12: 150. https://doi.org/10.3389/fnagi.2020.00150
[27]	Rahman MA, Rahman MS, Uddin MJ, et al. (2020) Emerging risk of environmental factors: insight mechanisms of Alzheimer's diseases. Environ Sci Pollut Res Int 27: 44659-44672. https://doi.org/10.1007/s11356-020-08243-z
[28]	Farrer LA, Cupples LA, Haines JL, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 278: 1349-1356. https://doi.org/10.1001/jama.1997.03550160069041
[29]	Heffernan AL, Hare DJ (2018) Tracing environmental exposure from neurodevelopment to neurodegeneration. Trends Neurosci 41: 496-501. https://doi.org/10.1016/j.tins.2018.04.005
[30]	Nisa FY, Rahman MA, Hossen MA, et al. (2021) Role of neurotoxicants in the pathogenesis of Alzheimer's disease: a mechanistic insight. Ann Med 53: 1476-1501. https://doi.org/10.1080/07853890.2021.1966088
[31]	Wild CP, Scalbert A, Herceg Z (2013) Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Environ Mol Mutagen 54: 480-499. https://doi.org/10.1002/em.21777
[32]	Turner MC, Vineis P, Seleiro E, et al. (2018) EXPOsOMICS: final policy workshop and stakeholder consultation. BMC Public Health 18: 260. https://doi.org/10.1186/s12889-018-5160-z
[33]	Warth B, Spangler S, Fang M, et al. (2017) Exposome-scale investigations guided by global metabolomics, pathway analysis, and cognitive computing. Anal Chem 89: 11505-11513. https://doi.org/10.1021/acs.analchem.7b02759
[34]	Xue J, Lai Y, Liu CW, et al. (2019) Towards mass spectrometry-based chemical exposome: current approaches, challenges, and future directions. Toxics 7: 41. https://doi.org/10.3390/toxics7030041
[35]	Metz TO, Baker ES, Schymanski EL, et al. (2017) Integrating ion mobility spectrometry into mass spectrometry-based exposome measurements: what can it add and how far can it go?. Bioanalysis 9: 81-98. https://doi.org/10.4155/bio-2016-0244
[36]	Stecker M, Segelnick J, Wilkenfeld M (2014) Analysis of short-term effects of world trade center dust on rat sciatic nerve. J Occup Environ Med 56: 1024-1028. https://doi.org/10.1097/JOM.0000000000000296
[37]	Wilkenfeld M, Fazzari M, Segelnick J, et al. (2016) Neuropathic symptoms in World Trade Center disaster survivors and responders. J Occup Environ Med 58: 83-86. https://doi.org/10.1097/JOM.0000000000000619
[38]	Marmor M, Thawani S, Cotrina ML, et al. (2020) Case-Control Study of Paresthesia Among World Trade Center-Exposed Community Members. J Occup Environ Med 62: 307-316. https://doi.org/10.1097/JOM.0000000000001828
[39]	Vignon A, Salvador-Prince L, Lehmann S, et al. (2021) Deconstructing Alzheimer's Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?. Int J Mol Sci 22: 8769. https://doi.org/10.3390/ijms22168769
[40]	Rodriguez-Prieto A, Gonzalez-Manteiga A, Dominguez-Canterla Y, et al. (2021) A Scalable Method to Study Neuronal Survival in Primary Neuronal Culture with Single-cell and Real-Time Resolution. J Vis Exp 173: e62759. https://doi.org/10.3791/62759
[41]	Klinghammer K, Walther W, Hoffmann J (2017) Choosing wisely - Preclinical test models in the era of precision medicine. Cancer Treat Rev 55: 36-45. https://doi.org/10.1016/j.ctrv.2017.02.009
[42]	Barrett JP, Olivari BS, Price AB, et al. (2021) Cognitive decline and dementia risk reduction: Promoting healthy lifestyles and blood pressure control. Am J Prev Med 61: e157-e160. https://doi.org/10.1016/j.amepre.2021.03.005

Reader Comments

Your name:*

Email:*
© 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)